↓ Skip to main content
What is this page? Embed badge

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma…

Overview of attention for article published in BMC Cancer, August 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
84 Mendeley
Summary X Dimensions citations
So far, Dimensions has found 21 publications that cite this research output.

21

The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.